<DOC>
	<DOCNO>NCT02891278</DOCNO>
	<brief_summary>This Phase I study goal determine feasibility , safety , toxicity administer sertraline combination timed-sequential cytosine arabinoside ( ara-C ) adult relapse refractory acute myeloid leukemia . Primary objective : - To define maximum tolerate dose ( MTD ) Recommended Phase II Dose ( RP2D ) sertraline administer combination timed-sequential cytosine arabinoside adult patient relapse refractory acute myeloid leukemia . - To evaluate safety tolerability sertraline give combination timed-sequential cytosine arabinoside adult patient relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Sertraline Cytosine Arabinoside Adults With Relapsed Refractory AML</brief_title>
	<detailed_description>Relapsed refractory acute myeloid leukemias characterized net drug resistance . At root drug resistance enhance survival relates intrinsic cell cycle dysregulation aberration overall process repair DNA damage . These malignancy represent continue therapeutic challenge , since currently `` standard treatment '' disease exist . Approximately 30 % adult newly diagnose AML primary refractory chemotherapy least 50 % achieve remission relapse . For patient relapsed refractory AML , expect CR/CRi rate traditional multi-agent chemotherapy range &lt; 10 % primary refractory AML 25-30 % relapsed AML cure rate &lt; 20 % , even allogeneic stem cell transplantation . Thus , novel treatment approach need .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Pathologicallyconfirmed diagnosis relapse AML : Patients AML relapse least primary induction failure eligible Age ≥ 18 ≤ 70 year ECOG Performance Status 0 2 ≥ 2 week cytotoxic chemotherapy ≥ 2 week radiation therapy Off biologic therapy include hematopoietic growth factor ≥ 1 week If use hydroxyurea , tyrosine kinase inhibitor ( TKIs ) /src inhibitor ( include FLT3 inhibitor ) , noncytotoxics , leukopheresis blast count control , patient must therapies &gt; 24 hr start sertraline Adequate organ function define : Renal function : Serum creatinine &lt; 2.0 mg/dL creatinine clearance ≥ 50 mL/minute Hepatic function : AST , ALT Alkaline Phosphatase ≤ 5x Upper Limit normal ( ULN ) , bilirubin ≤ 2.0 mg/dl , unless due Gilbert 's , hemolysis leukemic infiltration Left Ventricular Ejection Fraction ≥ 45 % MUGA Echocardiogram Patients undergone stem cell transplantation ( SCT ) , autologous allogeneic , eligible provide ≥ 8 week stem cell infusion , active GVHD , immune suppression least 2 week , history VOD Female patient childbearing age must negative pregnancy test Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry 30 day study participation Patients must able give informed consent Concomitant chemotherapy , radiation therapy , immunotherapy Patients receive investigational agent concurrently Hyperleukocytosis ≥ 30,000 blasts/uL . If use hydroxyurea , tyrosine kinase/src inhibitor ( include FLT3 inhibitor ) , noncytotoxics , leukopheresis blast count control , patient must therapies ≥ 24 hour prior begin sertraline Acute Progranulocytic Leukemia ( APL , M3 ) Active CNS leukemia Active , uncontrolled infection . Patients infection active treatment control antibiotic eligible Presence lifethreatening illness Patients mental deficit and/or psychiatric history preclude give informed consent follow protocol Pregnant woman exclude study due potential teratogenic and/or abortifacient effect combination chemotherapy . Nursing mother stop breastfeeding eligible due potential risk adverse event nurse infant Subjects follow cardiac risk factor must exclude : transmural MI within prior 6 month , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , cerebrovascular accident TIA seizure disorder within 6 month prior study drug administration . In addition , patient NYHA class III IV heart failure exclude Patients require treatment antidepressive medication include selective nonselective MAO inhibitor ( include linezolid ) , 5 HT receptor agonist ( triptans ) , tryptophan antidopaminergic agent ( antipsychotic , metoclopramide , promethazine , haloperidol ) Patients require prolonged treatment fluconazole , voriconazole , posaconazole . Use isavuconazonium sulfate , liposomal amphotericin , echinocandins permitted Prior treatment clofarabine within 6 month history clofarabineinduced liver dysfunction History hypersensitivity sertraline Patients take sertraline time study entry eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>leukemia</keyword>
</DOC>